Gossamer Bio (GOSS) Share-based Compensation (2018 - 2026)

Gossamer Bio has reported Share-based Compensation for 9 years, with the latest figure at $38.9 million in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 1405.61% year-over-year to $38.9 million in Q2 2026; TTM through Jun 2026 was $50.8 million, a 243.31% increase from a year earlier, with the FY2025 full-year figure at $10.6 million, down 48.81% from the prior year.
• Share-based Compensation was $38.9 million for Q2 2026 at Gossamer Bio, up from $6.3 million in the prior quarter.
• The five-year high for Share-based Compensation was $38.9 million in Q2 2026, with the low at $2.4 million in Q1 2025.
• Average Share-based Compensation over 5 years is $8.2 million, with a median of $6.1 million recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Share-based Compensation slumped 58.61% in 2025, then jumped 1405.61% in 2026.
• Over 5 years, Share-based Compensation stood at $11.4 million in 2022, then sank by 47.31% to $6.0 million in 2023, then retreated by 17.69% to $5.0 million in 2024, then plunged by 41.63% to $2.9 million in 2025, then surged by 1243.51% to $38.9 million in 2026.
• The last three Share-based Compensation figures came in at $38.9 million (Q2 2026), $6.3 million (Q1 2026), and $2.9 million (Q4 2025), per Business Quant data.